title: Enhancement of transdermal penetration and bioavailability of poorly soluble acyclovir using solid lipid nanoparticles incorporated in gel cream.
abstract: The objective of this work was to increase the amount of acyclovir in the basal epidermis, site of herpes virus simplex infection, using the solid lipid nanoparticles loaded gel cream as carriers. Solid lipid nanoparticles were prepared by high pressure homogenisation method and incorporated in a semisolid submicron gel cream. Acyclovir distribution into rat skin after topical application of solid lipid nanoparticles loaded gel cream was determined by fabricated Franz diffusion cell. The results showed that, the quantity of the acyclovir in the basal epidermis with the solid lipid nanoparticles loaded submicron gel cream was two folds times more than marketed acyclovir gel cream. This type of carrier can improve acyclovir loaded therapy since it increases drug retention in the basal epidermis.
authors.affiliation: Department of Pharmaceutical Science, Jawarlal Nehru Technological University, Kukatpally, Hyderabad-500 085, India.
authors.forename: P S
authors.initials: PS
authors.lastname: Gide
authors.forename: S K
authors.initials: SK
authors.lastname: Gidwani
authors.forename: K U
authors.initials: KU
authors.lastname: Kothule
keywords: Acyclovir; homogenisation; medium chain triglyceride; solid lipid nanoparticles
references.citation: J Drug Target. 2002 Sep;10(6):489-95
references.pmid: 12575739
references.citation: Int J Pharm. 2007 Jan 10;328(2):191-5
references.pmid: 16978810
references.citation: Eur J Pharm Sci. 2001 Sep;14(2):101-14
references.pmid: 11500256
references.citation: Pharm Res. 1995 Nov;12(11):1623-7
references.pmid: 8592660
references.citation: Eur J Pharm Biopharm. 1998 Jan;45(1):23-9
references.pmid: 9689532
references.citation: Biomaterials. 2006 Jun;27(18):3491-6
references.pmid: 16513163
references.citation: Lipids Health Dis. 2009 Feb 26;8:6
references.pmid: 19243632
references.citation: Antiviral Res. 2001 Oct;52(1):19-24
references.pmid: 11530184
references.citation: J Invest Dermatol. 1992 Jun;98(6):856-63
references.pmid: 1593149
references.citation: J Control Release. 2006 Jan 10;110(2):296-306
references.pmid: 16325954
references.citation: Pharmazie. 2001 Oct;56(10):783-6
references.pmid: 11683123
references.citation: Am J Med. 1982 Jul 20;73(1A):315-9
references.pmid: 6285721
references.citation: J Pharm Pharmacol. 2001 Oct;53(10):1311-22
references.pmid: 11697538
references.citation: Int J Pharm. 2000 Mar 10;196(2):165-7
references.pmid: 10699710
references.citation: Adv Drug Deliv Rev. 2002 Nov 1;54 Suppl 1:S41-55
references.pmid: 12460715
references.citation: Eur J Pharm Biopharm. 2003 Sep;56(2):189-96
references.pmid: 12957632
references.citation: J Pharm Sci. 1985 Jun;74(6):688-9
references.pmid: 4020657
references.citation: J Control Release. 2004 Jul 7;97(3):493-502
references.pmid: 15212881
references.citation: Adv Drug Deliv Rev. 2004 Mar 27;56(5):675-711
references.pmid: 15019752
references.citation: J Control Release. 1998 Jan 2;50(1-3):291-6
references.pmid: 9685896